Arctic Vision is a clinical-stage specialty ophthalmology company based in Shanghai and led by Founder and CEO Dr. Eddy Wu. The company focuses on developing therapies for pan-ocular diseases and holds a portfolio of three late-stage in-licensed products: ARVN001 for uveitic macular edema (UME), ARVN002 for pediatric progressive myopia, and ARVN003 for presbyopia. It completed an over US$100m Series B to advance its clinical programs. Proceeds will support clinical developments, registrational activities and commercialization efforts. The financing will also fund the establishment of in-house R&D capabilities, business development, and organizational growth.

Total raised

$100M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2021